Salubris(SZ:002294)2022-12-07 08:31Group 1: Product Development and Market Position - The company is actively promoting and bidding for Aliskiren, expecting it to enter more provinces as bidding progresses [3] - Efforts are underway to include Aliskiren in the medical insurance directory, which significantly impacts sales [3] - The growth of Taijia is attributed to its quality and efficacy, gaining recognition among medical experts and patients [4] Group 2: Sales and Market Trends - Currently, Taijia has no sales in Guangdong due to bidding policies, but the company believes in the product's market position [3] - The PCI surgery volume in China is expected to continue growing, providing a broad market for Taijia as a pre- and post-operative medication [4] - The company anticipates sustained growth in Taijia's sales due to increasing demand in therapeutic prevention and neurology [4] Group 3: Clinical Development and Future Plans - The recombinant human parathyroid hormone 1-34 (rhPTH1-34) is currently in the III clinical stage [5] - The company is building a biopharmaceutical R&D platform and plans to introduce more talented researchers and products [5] - The establishment of a commercial insurance company is in the application stage, leveraging the company's experience in the healthcare sector [5] Group 4: Compliance and Communication - During the investor relations activity, the company ensured compliance with regulations and did not disclose any undisclosed significant information [6]